By Taylor Mixides (Drug Target Review)2023-07-05T16:00:25
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2026-03-11T14:00:00
Sponsored by Merck
2023-03-28T11:38:32
Sponsored by Bio-Techne
2025-11-19T16:00:00
Sponsored by Eurofins DiscoverX
2026-08-24T08:43:00
Author Dr Dana Watt
2026-03-25T15:00:00
Sponsored by Yokogawa
Site powered by Webvision Cloud